ARS Pharmaceuticals, Inc. Logo

ARS Pharmaceuticals, Inc.

Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.

SPRY | US

Overview

Corporate Details

ISIN(s):
US82835W1080
LEI:
Country:
United States of America
Address:
11682 EL CAMINO REAL, SUITE 300, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for patients with severe allergic reactions. The company is dedicated to creating patient-friendly, needle-free therapies to address challenges such as device portability, ease of use, and needle-related risks. Its lead product, neffy® (epinephrine nasal spray), is the first and only FDA-approved needle-free epinephrine product for the emergency treatment of Type I allergic reactions. neffy is designed as a non-invasive and easy-to-carry alternative to traditional auto-injectors, empowering patients and caregivers to administer treatment without hesitation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ARS Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ARS Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ARS Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan
4597
SOLENO THERAPEUTICS INC Logo
Develops novel therapeutics for rare diseases like Prader-Willi syndrome.
United States of America
SLNO
Sol-Gel Technologies Ltd. Logo
Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.
United States of America
SLGL
Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO

Talk to a Data Expert

Have a question? We'll get back to you promptly.